Scarica l'app Stockscreener
24.35
1.97%
0.47
Dopo l'orario di chiusura:
24.35
Precedente Chiudi:
$23.88
Aprire:
$23.89
Volume 24 ore:
952.99K
Relative Volume:
1.12
Capitalizzazione di mercato:
$2.10B
Reddito:
$23.38M
Utile/perdita netta:
$-155.22M
Rapporto P/E:
-11.12
EPS:
-2.19
Flusso di cassa netto:
$-134.36M
1 W Prestazione:
+3.09%
1M Prestazione:
-5.25%
6M Prestazione:
-43.44%
1 anno Prestazione:
-44.06%
Intervallo 1D:
$23.88
$24.97
Intervallo di 1 settimana:
$23.34
$24.97
Portata 52W:
$22.10
$47.73
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Nome
Ideaya Biosciences Inc
Settore
Industria
Telefono
650-443-6209
Indirizzo
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta IDYA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
24.35 | 2.10B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-11-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2024-03-08 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Outperform |
| 2023-05-24 | Iniziato | Goldman | Buy |
| 2023-04-24 | Aggiornamento | Stifel | Hold → Buy |
| 2023-03-23 | Iniziato | Berenberg | Buy |
| 2023-02-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-28 | Iniziato | CapitalOne | Overweight |
| 2022-10-27 | Iniziato | Citigroup | Buy |
| 2022-08-15 | Downgrade | Stifel | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-10 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-11 | Iniziato | Guggenheim | Buy |
| 2020-10-07 | Iniziato | Wedbush | Outperform |
| 2020-09-01 | Iniziato | Northland Capital | Outperform |
| 2020-07-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-06 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-13 | Iniziato | ROTH Capital | Buy |
| 2019-10-17 | Iniziato | Oppenheimer | Outperform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-17 | Iniziato | Citigroup | Buy |
| 2019-06-17 | Iniziato | JP Morgan | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
Mostra tutto
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
IDYAIDEAYA Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
IDEAYA Awards Strategic Stock Options Package: Key Details for New Hires Revealed - StockTitan
12 Stocks That Will Double in 2025 - Insider Monkey
Uncover the Top 12 Stocks Set to Skyrocket by 2025! - Reporteros del Sur -
Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025 - Insider Monkey
BTIG reiterates Buy on Ideaya stock, cites significant updates - MSN
Mizuho Initiates Coverage of IDEAYA Biosciences (IDYA) with Outperform Recommendation - MSN
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events - Nasdaq
IDEAYA Biosciences to Present at Major Healthcare Investment Conferences - StockTitan
(IDYA) Technical Data - Stock Traders Daily
Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation - Yahoo Finance
Cantor Fitzgerald Weighs in on IDYA FY2025 Earnings - Defense World
Brokers Issue Forecasts for IDYA FY2025 Earnings - MarketBeat
BTIG reiterates Buy on Ideaya stock, cites significant updates By Investing.com - Investing.com Canada
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Holdings Lifted by JPMorgan Chase & Co. - Defense World
JPMorgan Chase & Co. Grows Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Ideaya stock touches 52-week low at $22.15 amid market challenges - MSN
Short Interest in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Expands By 10.1% - MarketBeat
IDEAYA Biosciences (IDYA): A Down Year Presents a Window of Opportunity for Investors - MSN
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year LowHere's Why - MarketBeat
IDEAYA Biosciences’ (IDYA) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World
Ideaya stock touches 52-week low at $22.15 amid market challenges By Investing.com - Investing.com South Africa
Leerink Partners Downgrades IDEAYA Biosciences (IDYA) - MSN
Learn to Evaluate (IDYA) using the Charts - Stock Traders Daily
Royal Bank of Canada Reaffirms "Outperform" Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Given “Overweight” Rating at Cantor Fitzgerald - Defense World
IDEAYA Biosciences (NASDAQ:IDYA) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance - The Malaysian Reserve
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance – Company Announcement - Financial Times
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 12-Month Low – Here’s Why - Defense World
IDEAYA Biosciences Unveils Ambitious 2025 Growth Plan, $1.2B Cash Position Funds Through 2028 - StockTitan
Ideaya Biosciences stock hits 52-week low at $24.14 By Investing.com - Investing.com Australia
IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 1-Year LowShould You Sell? - MarketBeat
Ideaya Biosciences stock hits 52-week low at $24.14 - Investing.com
Analysts Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Price Target at $53.67 - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
IDEAYA Biosciences' SWOT analysis: oncology biotech stock's potential and risks - Investing.com Australia
IDEAYA Biosciences' SWOT analysis: oncology biotech stock's potential and risks By Investing.com - Investing.com South Africa
Principal Financial Group Inc. Sells 4,968 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences (NASDAQ:IDYA) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Another Major DLL3 ADC Alliance As Hengrui Links With IDEAYA - News & Insights
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals - BioPharma Dive
IDEAYA Biosciences in-licenses Hengrui’s SHR-4849 - The Pharma Letter
Ideaya, Hengrui join hands in $1B deal for phase I ADC targeting DLL3 - BioWorld Online
IDEAYA Biosciences Enters into Exclusive License Agreement with Hengrui Pharma - Defense World
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - Kilgore News Herald
Ideaya Biosciences stock hits 52-week low at $24.38 By Investing.com - Investing.com Nigeria
Ideaya Biosciences Inc Azioni (IDYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):